Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Eric Horwitz

Center AffiliationsMolecular Therapeutics

Publications (214) (print view)

no pagination
Feigenberg SJ, Hanlon AL, Horwitz EM, Pollack A. Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2 Suppl):S176.
Hammond E, Berkey BA, Fu KK, Trotti A, Meredith RF, Jones CU, Byhardt R, Horwitz EM, Ang KK, Radiation Therapy Oncology G. p105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: A clinical/laboratory correlative analysis of RTOG-9003. International Journal of Radiation Oncology Biology Physics. 2003 Nov;57(3):683-92.
Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. Journal of Clinical Oncology. 2003 Nov;21(21):3972-8.
Horwitz EM. Conformal radiotherapy with dose escalation appears safe and effective in localised prostate cancer. Cancer Treat Rev. 2003 Jun;29(3):219-21.
Horwitz EM, Mitra RK, Uzzo RG, Das IJ, Pinover WH, Hanlon AL, McNeeley SW, Hanks GE. Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants. Radiother Oncol. 2003 Feb;66(2):173-9.
Horwitz EM, Uzzo RG, Hanlon AL, Greenberg RE, Hanks GE, Pollack A. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. Journal of Urology. 2003 Jun;169(6):2153-7.
Horwitz EM, Uzzo RG, Miller N, Theodorescu D. Brachytherapy for prostate cancer follow-up and management of treatment failures. Urologic Clinics of North America. 2003 Nov;30(4):737--50, viii-ix.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with >15% risk of pelvic lymph-node involvement [meeting abstract]. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2 Suppl):S150.
Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28.
Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2):391-401.
Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2):377-83.
Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer. 2003 Feb 15;97(4):1127-33.
Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World journal of urology. 2003 Sep;21(4):200-8.
Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Sep;57(1):19-23.
Pollack A, Horwitz EM, Movsas B. Treatment of prostate cancer with regional lymph node (N1) metastasis. Semin Radiat Oncol. 2003 Apr;13(2):121-9.
Pollack A, Horwitz EM, Movsas B, Hanlon AL. Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment. The Urologic clinics of North America. 2003 May;30(2):337-49.
Price RA, Murphy S, McNeeley SW, Charlie CM, Horwitz E, Movsas B, Raben A, Pollack A. A method for increased dose conformity and segment reduction for sMLC delivered IMRT treatment of the prostate. International Journal of Radiation Oncology Biology Physics. 2003 Nov;57(3):843-52.
Ridge JA, Glisson BS, Horwitz EM, Meyers M. Head and neck tumors. In: Ridge JA, Glisson BS, Horwitz EM, Meyers M, editors. Cancer management : a multidisciplinary approach : medical, surgical, & radiation oncology. New York: Oncology Group; 2003. p. 39-85.
Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43.
Uzzo RG, Cairns P, Leavis P, Dulin N, Horwitz EM, Pollack A, Kolenko V. Tumor resistance to apoptosis: Mechanisms of evasion and implications for radiation and chemotherapeutic strategies. In: Finke JH, Bukowski RM, editors. Cancer immunotherapy at the crossroads : how tumors evade immunity and what can be done. Totowa, N.J.: Humana Press; 2003. p. 215-33.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Eric Horwitz Sparkline Graph

Graph Interactions


Similar Investigators:

Keywords (MeSH):

Last updated on Tuesday, June 05, 2018